Physician profile
Paul Leis
NPI 1871913830
$5,203.08
in general payments reported to CMS, 2019-2025
25 companies · $414 in 2025
The $414 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $1,760 · 2021: $820 · 2022: $324 · 2023: $213 · 2024: $391 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.92 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $876.24 | 2020-2022 | |
| Abiomed | $778.15 | 2019-2020 | |
| Amgen INC. | $733.77 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $297.31 | 2019-2024 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.30 | 2020-2025 | Jardiance |
| Abbott Laboratories | $263.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $243.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $206.45 | 2020-2022 | |
| Astellas Pharma US INC | $200.51 | 2019-2021 | |
| Elucid Bioimaging INC | $150.00 | 2025 | Plaqueiq |
| Esperion Therapeutics, INC. | $149.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.82 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $90.21 | 2024 | Arcalyst |
| Akcea Therapeutics, INC. | $87.81 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.62 | 2024-2025 | Verquvo |
| Philips North America LLC | $77.91 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $75.42 | 2021-2025 | Onpattro |
| Lantheus Medical Imaging, INC. | $58.78 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $49.40 | 2023 | Inpefa |
| Pfizer INC. | $43.87 | 2019-2020 | |
| Endotronix, INC. | $31.19 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
| E.R. Squibb & Sons, L.L.C. | $19.61 | 2020 | |
| Medtronic, INC. | $18.87 | 2021 | |
| Nuwellis, INC. | $17.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Leis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.